WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that new clinical data will be reported at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting with three targeted anticancer compounds in development by the Company and its collaborators. The ASCO annual meeting will be held May 30 to June 3, 2008 in Chicago, IL.
